硫秋水仙苷(Thiocolchicoside) - 药物靶点：GABAA receptor_在研适应症：肌肉痉挛_专利_临床

概要

基本信息

药物类型

小分子化药

别名

TCC、Thiocolchicine 2-glucoside analog、Thiocolchicoside (INN)

+ [4]

靶点

GABAA receptor

作用机制

GABAA receptor拮抗剂(γ-氨基丁酸 A 受体拮抗剂)

治疗领域

神经系统疾病皮肤和肌肉骨骼疾病

在研适应症

肌肉痉挛

非在研适应症-

原研机构-

在研机构-

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C27H33NO10S

InChIKeyLEQAKWQJCITZNK-AXHKHJLKSA-N

CAS号602-41-5

关联

15

项与硫秋水仙苷相关的临床试验

NCT06261320 / Active, not recruiting临床2期

Mesotherapy Treatment of Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a gastrointestinal transit disorder characterized by chronic abdominal pain and impaired transit in the absence of demonstrated organic disease. Considered a non-fatal disease, its effects relate more to quality of life, work production and health care systems.
Given the complexity of this disease, no treatment has been recognized as standard treatment. The treatment is rather focused on treating the symptoms caused (chronic pain or intestinal transit disorder). In general, therapy is considered individualized and includes lifestyle/diet modifications and pharmaceutical therapy.
Several published case studies evaluating the effect of mesotherapy on improving the severity of the disease have demonstrated an improvement in the symptoms of this syndrome. Due to the limited number of case studies and the insufficient level of evidence to conclude, our study will therefore be a before-and-after intervention study, to evaluate the effect of four mesotherapy sessions on the treatment of IBS symptoms.

开始日期2024-02-28

申办/合作机构

Polyclinique de l'Europe SASU

CTRI/2022/12/047988 / Not yet recruitingN/AIIT

Evaluating Pre-Emptive Analgesia of Etoricoxib, Thiocolchicoside and Dexamethasone in Lower Third Molar Surgery A Randomised Controlled Trail

开始日期2022-12-11

申办/合作机构-

CTRI/2022/07/043690 / Recruiting临床4期

A Prospective, Randomized, Parallel Group, Open Label, Multi-centric, Active Controlled Study to Evaluate the Efficacy and Safety of fixed dose combination of Etoricoxib(60mg) and Thiocolchicoside (4mg) vs Chlorzoxazone(500mg) and Diclofenac(50mg) and Paracetamol(325mg) in Low Back Pain.

开始日期2022-07-06

申办/合作机构

Mankind Pharma Ltd.

100 项与硫秋水仙苷相关的临床结果

登录后查看更多信息

100 项与硫秋水仙苷相关的转化医学

登录后查看更多信息

100 项与硫秋水仙苷相关的专利（医药）

登录后查看更多信息

658

项与硫秋水仙苷相关的文献（医药）

2024-12-31·Journal of Dermatological Treatment

Postoperative risk assessment of post-inflammatory hyperpigmentation and the efficacy of delayed prevention following 532 nm Q-switched Nd:YAG laser treatment of solar lentigines: a randomized controlled study

Article

作者: Lew, Bark-Lynn ; Lee, Yoonsung ; Choi, Sang-min ; Kim, Man S. ; Kang, Da-Hyun ; Kwon, Soon-Hyo

BACKGROUNDAlthough post-inflammatory hyperpigmentation (PIH) is a common adverse event following laser procedures, studies evaluating its risk remain limited.OBJECTIVETo analyze PIH risk after 532 nm Q-switched Nd:YAG laser (QSNYL) treatment for solar lentigines and examine the efficacy of triple combination cream (TCC) for its prevention.METHODSIn this single center, investigator-blinded, randomized controlled study, participants with solar lentigo either received TCC or emollient from 2 weeks post-QSNYL treatment. The occurrence of PIH was determined by three independent and blinded dermatologists. In vivo skin measurements and sun exposure questionnaires were examined to evaluate the risk of PIH.RESULTSA total of 28 patients with 67 solar lentigines were included in the analysis. In the control group, PIH occurred in 55.3% of the lesions. Risk factors for the occurrence of PIH were the increased erythema at weeks 2 (OR, 1.32; p = 0.035) and outdoor activity during 1-5 pm (OR, 8.10; p = 0.038). Treatment with TCC from 2 weeks post-QSNYL treatment significantly decreased the incidence of PIH (31.0% vs. 55.3%, p = 0.048).CONCLUSIONPost-laser erythema and outdoor activity at the daytime are prognostic factors for the occurrence of PIH. Administering TCC could be considered for the prevention of PIH in high-risk patients.

2024-12-31·Renal Failure

The role of hemodialysis access in intradialysis and interdialysis vital sign variabilities and the development of dialysis headache

Article

作者: You, Nujia ; Xiong, Yuqin ; Liao, Ruoxi ; Yu, Yang ; Qin, Shuoyue

To determine the relationship of hemodialysis access with vital sign variability and hemodialysis-related headache (HRH). Adult outpatients receiving maintenance hemodialysis (MHD) were prospectively recruited, and 12 consecutive dialysis sessions were monitored. Intradialysis (hour-to-hour) and interdialysis (dialysis day-to-day) vital sign variabilities were assessed via three metrics: the difference between the maximum and minimum values, average real variability (ARV), and residuals. Multivariate logistic regression analysis was used to explore the factors triggering HRH. A total of 91 Chinese MHD patients (60.4% male) aged 58.5 ± 17.2 years were included, with 59 patients using radiocephalic arteriovenous fistulas (RCAVFs) and 32 patients using tunneled cuffed catheters (TCCs) for dialysis. The median dialysis vintage was 26.8 (12.0-44.7) months. Compared with the RCAVF group, the TCC group had significantly greater urea reduction (71.1 ± 9.3% vs. 61.7 ± 10.5%, p < 0.001) and clearance (1.5 (1.2-1.8) vs. 1.1 (1.0-1.4), p < 0.001) rates, higher intradialysis pulse variability and lower intradialysis diastolic blood pressure variability. Some of interdialysis variability indexes in pulse, systolic blood pressure (SBP), and SpO2 were significantly greater in the TCC group than that in the RCAVF group. Age (OR = 0.880, 95% CI = 0.785-0.986, p = 0.028), TCC use (OR = 22.257, 95% CI = 1.190-416.399, p = 0.038), intradialysis SBP-ARV (OR = 2.768, 95% CI = 1.069-7.171, p = 0.036), and blood sodium level (OR = 0.400, 95% CI = 0.192-0.832, p = 0.014) were shown to be independent risk factors for HRH. In conclusion, the use of TCCs has multifaceted effects on intradialysis and interdialysis vital sign variabilities and is independently associated with an increased risk of HRH.

2024-12-01·Journal of Hazardous Materials

Triclocarban disrupts the activation and differentiation of human CD8+ T cells by suppressing the vitamin D receptor signaling

Article

作者: Zhang, Xingwei ; Chang, Yiming ; Chen, Zhixi ; Li, Yangqiu ; Sun, Guodong ; Li, Xinye ; Zhang, Yikai ; Liu, Zirui ; Zha, Xianfeng ; Guo, Jiafan

Triclocarban (TCC) is a widely applied environmental endocrine-disrupting chemical (EDC). Similar to most of EDCs, TCC potentially damages the immunity of various species. However, whether and how TCC impacts the adaptive immunity in mammals has yet to be determined. Herein, we discovered that TCC disrupts the activation and differentiation of CD8⁺ T cells in primary human peripheral blood samples, purified CD8⁺ T cells, and in mice in vivo. Mechanistically, TCC might block the activation of the vitamin D receptor (VDR) and reduce the synthesis of cholesterol, a precursor of vitamin D, resulting in inhibition of VDR signaling due to the suppression of both its ligand and the receptor itself by TCC. Our findings elucidate the hazard and potential mechanisms of TCC in mammalian adaptive immunity and highlighted VDR as a potential therapeutic target for the immunodeficiency caused by TCC.

100 项与硫秋水仙苷相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07276	硫秋水仙苷	M03BX05	DB11582

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肌肉痉挛	-	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


IEC2007	N/A	-	-	Thiocolchicoside	艱積鏇繭鬱壓鬱壓構壓(鹹觸獵衊鑰遞糧簾願範) = 獵構夢鑰艱蓋齋鏇夢壓壓構鑰積廠艱衊艱蓋製 (範夢築簾築獵遞範壓築 ) 更多	-	2007-07-07
EULAR2002	N/A	急性腰痛	-	Thiocolchicoside	(鹹鬱蓋醖壓襯築築壓餘) = 繭齋鬱觸餘憲膚膚構獵齋獵艱壓憲選襯鏇窪艱 (願衊鏇構憲壓繭餘構糧 ) 更多	积极	2002-06-12
EULAR2002	N/A	急性腰痛	-	Tizanidine	(鹹鬱蓋醖壓襯築築壓餘) = 觸艱蓋鬱觸夢夢願觸選齋獵艱壓憲選襯鏇窪艱 (願衊鏇構憲壓繭餘構糧 ) 更多	积极	2002-06-12